| Drug Name |
Sotorasib |
| Drug ID |
BADD_D02596 |
| Description |
Sotorasib, also known as AMG-510, is an acrylamide derived KRAS inhibitor developed by Amgen.[A187547,A187556] It is indicated in the treatment of adult patients with KRAS G12C mutant non small cell lung cancer.[L34288] This mutation makes up >50% of all KRAS mutations.[A187550] Mutant KRAS discovered in 1982 but was not considered a druggable target until the mid-2010s.[A235168] It is the first experimental KRAS inhibitor.[A187547]
The drug [MRTX849] is also currently being developed and has the same target.[A187547]
Sotorasib was granted FDA approval on 28 May 2021.[L34288] |
| Indications and Usage |
Sotorasib is indicated in the treatment of adults with KRAS G12C mutant non small cell lung cancer.[L34288] |
| Marketing Status |
approved; investigational |
| ATC Code |
L01XX73 |
| DrugBank ID |
DB15569
|
| KEGG ID |
D12055
|
| MeSH ID |
C000706028
|
| PubChem ID |
137278711
|
| TTD Drug ID |
D0R7LD
|
| NDC Product Code |
50683-0573; 55513-504; 69988-0057; 55513-488; 58272-065 |
| UNII |
2B2VM6UC8G
|
| Synonyms |
sotorasib | lumakras | AMG-510 | AMG 510 | AMG510 | 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one |
